Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Non-Current Assets: 2022-2025

Historic Non-Current Assets for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $2.7 million.

  • InMed Pharmaceuticals' Non-Current Assets fell 19.59% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 19.59%. This contributed to the annual value of $2.7 million for FY2025, which is 13.42% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Non-Current Assets of $2.7 million as of FY2025, which was down 13.42% from $3.1 million recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Non-Current Assets registered a high of $3.2 million during FY2022, and its lowest value of $2.7 million during FY2025.
  • Its 3-year average for Non-Current Assets is $2.9 million, with a median of $2.8 million in 2023.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Non-Current Assets grew by 12.92% in 2024, and later fell by 13.42% in 2025.
  • Yearly analysis of 4 years shows InMed Pharmaceuticals' Non-Current Assets stood at $3.2 million in 2022, then decreased by 13.02% to $2.8 million in 2023, then grew by 12.92% to $3.1 million in 2024, then dropped by 13.42% to $2.7 million in 2025.